OREANDA-NEWS The Federal Antimonopoly Service (FAS) of Russia has agreed on the price of the first domestic generic drug "Ertugliflozin" under the international nonproprietary name (INN) of the same name, which is used to treat insufficiently controlled type 2 diabetes mellitus, the agreed price is almost 13% lower relative to the registered cost of the foreign reference drug Stiglatra, the agency reported.

"FAS: prices for a drug for the treatment of diabetes mellitus have been reduced by 12.79%. We are talking about the first generic drug of domestic production, Ertugliflozin, within the framework of the INN of the same name... The prices agreed by the Federal Antimonopoly Service are on average 12.79% lower than the minimum prices for the reference drug Stiglatra," the report says.

It is noted that Ertugliflozin is used to treat adult patients with insufficiently controlled type 2 diabetes mellitus in addition to diet and exercise.